In the dynamic arena of medical technology, where innovation holds profound implications for patient care, Inquis Medical is emerging as a notable player. This clinical-stage medical device company, renowned for its advanced thrombectomy systems, recently completed a successful $40 million Series B funding round. To gain insights into the significance of this achievement for the company and the broader medical landscape, I engaged in a discussion with Dr. Emily Turner, a senior research scientist at Inquis Medical.
Dr. Turner, embodying a blend of calm determination and passion, revealed the dedication behind Inquis Medical’s ascent. “It’s an exhilarating phase for us,” she remarked, her words reflecting her deep involvement in the company’s progress. “The Series B funding represents a crucial milestone, enabling us to advance our technologies and edge closer to commercialisation.”
At the heart of Inquis Medical’s innovation is the Aventus Precision Thrombectomy System, which epitomises their cutting-edge efforts. Dr. Turner elaborated on the system’s proprietary tissue-sensing technology, emphasising its ability to provide operators with real-time insights into tissue composition during procedures. “This precision and control are without precedent,” she stated with evident pride. “We aim to transcend the current limitations of thrombectomy systems and enhance patient outcomes.”
The funding round, spearheaded by the globally esteemed investment firm Marshall Wace, with participation from existing investors such as ShangBay Capital and Yu Star, highlights the confidence in Inquis Medical’s mission. Dr. Turner expressed appreciation for the endorsement: “Having Marshall Wace, particularly with Andrew D. Goldberg, MD, joining our Board of Directors, underscores the robustness of our technology and the calibre of our team.”
Our discussion naturally drifted towards the impact of this investment on health outcomes. In the United States alone, venous thromboembolism affects approximately one million people each year, with over half of deep vein thrombosis cases progressing to pulmonary embolism—a significant cardiovascular threat. “Our efforts extend beyond innovation for its own sake,” Dr. Turner stressed. “We are addressing tangible challenges and delivering solutions that can save lives.”
Earlier this year, Inquis Medical achieved a significant milestone with the FDA 510(k) clearance for the Aventus Thrombectomy System, a critical step forward. The company is also nearing the completion of enrolment in an FDA Investigational Device Exemption (IDE) pivotal clinical study focused on patients with pulmonary embolism. Dr. Turner emphasised the significance of these regulatory achievements: “Every clearance and study completion brings us closer to enabling physicians to access the technology they need.”
Looking forward, the Series B funding will facilitate Inquis Medical’s completion of its pivotal IDE trial and preparation for the commercial launch of the Aventus Thrombectomy System in 2025. “We have set an ambitious timeline,” Dr. Turner conceded, “but our commitment is unwavering. Our team is driven by the potential to elevate patient care and empower physicians with our unique technology.”
As our conversation reached its conclusion, I inquired about the company’s vision for the future. Dr. Turner paused, reflecting thoughtfully. “Innovation is central to our ethos,” she concluded. “Yet, it’s not solely about technology. It’s about making a tangible impact on patients’ lives. That mission propels us forward.”
Inquis Medical’s trajectory exemplifies the transformative power of innovation and investment in healthcare. With substantial financial backing and a clear vision for the future, the company stands ready to leave a lasting mark in the field of thrombectomy systems. For observers of this unfolding story, it serves as a reminder of the remarkable progress in medical technology and the unwavering dedication of those who work tirelessly to translate these advancements from concept to reality. Inquis Medical’s narrative is still unfolding, and their continued efforts promise an optimistic future for healthcare.
Be the first to comment